Comparison of bovine in vivo bioavailability of two sulfamethazine oral boluses exhibiting different in vitro dissolution profiles

The bolus (or oblet) is a dosage form that can be used for the oral administration of pharmaceutical compounds to ruminating species. Unlike traditional tablets, oral boluses may contain quantities of drug on the order of grams rather than milligrams. Due to its size, it is only recently that USP-like in vitro dissolution methods have been developed for this dosage form. However, whether or not these dissolution tests can predict product in vivo performance has yet to be determined. The importance of this issue is apparent when the U.S. Food and Drug Administration Center for Veterinary Medicine is faced with the decision of whether to require additional in vivo bioequivalence study data to support the approval of changes in product chemistry or manufacturing method. The current study was undertaken to determine whether an in vivo/in vitro correlation can be established for bovine sulfamethazine oral boluses and to acquire insight into the magnitude of changes in in vitro product performance that can occur before corresponding changes are seen in in vivo blood level profiles. Based upon the results of this investigation, it is concluded that marked changes in in vitro sulfamethazine bolus performance can be tolerated before resulting in altered in vivo blood level profiles. However, the data also suggest that rumenal absorption may occur for some compounds. Therefore the degree to which variation in product in vitro dissolution profiles can be tolerated may be compound specific.     

Drinking water as a medium for drugs

If drug treatment is necessary in large herd sizes, the administration with feed or drinking water is preferred. The use of the drinking water as a vehicle for drugs may be accompanied by several problems. An important condition for a successful medication is a good water solubility of the administered compound. The solubility is influenced by the quality of the used drinking water. The stability of the dissolved drug and incompatibilities with other water ingredients are additional limiting factors. The success of the treatment is influenced also by the taste of the medicated water which may cause a reduced water consumption. The use of tap water instead of spring water may be helpful to improve the efficacy of drug treatment via drinking water.     

细胞培养筛选抗球虫剂程序的研究

本文作者在Ｅｉｍｅｒｉａ ｔｅｎｅｌｌａ细胞培养模型上研究了评价抗球虫剂的程序，包括投药时间、效果评定指标、药物有效浓度及毒性浓度、细胞培养有效浓度及鸡体中使用浓度之相关性等内容。试验结果表明药物溶剂影响药物效能的发挥。投药于球虫培养全期比其他几种投药时间更能准确地评价各种药物的效果。药物评价的指标，除子孢子的活力及裂殖体形成数量之外，卵囊形成数量更能显示出药物的作用效果。本试验确定的药物筛选程序     

Determination of the in vitro susceptibility of feline tritrichomonas foetus to 5 antimicrobial agents

BACKGROUND: The nitroimidazole, ronidazole, has been demonstrated to have in vitro and in vivo activity against the protozoan Tritrichomonas foetus in cats. The purpose of this study was to evaluate the in vitro susceptibility of feline T. foetus isolates obtained from naturally infected cats to 5 antimicrobial agents and to compare the in vitro time kill of ronidazole and metronidazole. HYPOTHESIS: We hypothesized that nitroimidazoles have in vitro activity against T. foetus, whereas furazolidone, omeprazole, and paromomycin do not. ANIMALS: Fecal specimens were cultured from 4 naturally infected Bengal cats with a history of T. foetus-associated diarrhea. METHODS: A 24-hour susceptibility assay was performed on all 4 isolates for the 5 antimicrobial agents. A time-kill microdilution method was performed on 2 isolates for metronidazole and ronidazole. RESULTS: Paromomycin and omeprazole showed no in vitro effect at concentrations < or = 80 microg/mL. There was no significant difference in 24-hour susceptibilities among metronidazole, ronidazole, and furazolidone. In addition, only the results of the highest concentration tested (80 microg/mL) and concentrations of 1.25 and 2.5 microg/mL revealed significant differences in the rate of trophozoite killing, with ronidazole having a faster reduction in trophozoite survival. CONCLUSIONS AND CLINICAL IMPORTANCE: Time-kill assays demonstrated ronidazole had a higher lethal activity compared with metronidazole. These findings contrast with a previously published report and may reflect strain variation, different methodologies, or both. The lack of clinical response seen with metronidazole administration to treat feline trichomoniasis may not reflect inherent resistance but rather in vivo events involving drug distribution and pharmacokinetics.     

In vitro and ex vivo pharmacodynamics of selected non-steroidal anti-inflammatory drugs in equine whole blood

Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenases (COX), and the inhibition of COX-2 rather than COX-1 can limit the onset of NSAID-related adverse effects. The pharmacodynamic properties of eltenac, naproxen, tepoxalin, SC-560 and NS 398 in healthy horses were investigated using an in vitro whole blood assay. To predict COX selectivity in clinical use, eltenac and naproxen were also studied ex vivo after intravenous administration. SC-560 acted as a selective COX-1 inhibitor, tepoxalin as a dual inhibitor with potent activity against COX-1, and NS 398 as a preferential COX-2 inhibitor. Eltenac was a preferential COX-2 inhibitor in vitro but un-selective in the ex vivo study. Naproxen maintained its non-selectivity both in vitro and ex vivo. These findings have demonstrated that in vitro studies may not accurately predict in vivo NSAID selectivity for COX and should be confirmed using an ex vivo whole blood assay.     

硫酸多糖抗病毒作用研究进展

硫酸多糖是指糖羟基上带有硫酸根的多糖,可经天然提取或硫酸化的结构修饰而得到。近年的研究证明硫酸多糖无论在体内还是在体外,都显示了不同程度的抗病毒活性,尤其是与目前使用的其他抗病毒药物相比,其细胞毒作用较小而得到广泛的关注,其抗病毒作用机理是通过抑制病毒的吸附而阻止了合胞体的形成发挥作用的。通过筛选适宜大小分子量和结构改造,降低其毒副作用,硫酸多糖有望成为继病毒逆转录酶活性抑制剂、蛋白酶抑制剂后的又一类潜在的新型抗病毒药物,将在抗病毒感染方面显示出重要的作用,具有广阔的应用前景。文章就近年来国内外硫酸多糖的抗病毒作用进行了综述。     

In vitro and in vivo effects of chlorpyrifos and cypermethrin on blood cholinesterases in sheep

The combination of the organophosphate (OP) chlorpyrifos (CPF) and the pyrethroid cypermethrin (CPM) is commonly marketed as pour‐on formulations for the control of sheep lice, ked, and blowflies. CPF irreversibly inhibits acetylcholinesterases (AChE), while pyrethroids are not AChE inhibitors. However, combinations of pyrethroids with OPs showed a highly synergistic effect on AChE inhibition. Thus, the aim of the current work was to evaluate in vitro and in vivo the inhibitory potency of both pesticides, alone and in combination with AChE and butyrylcholinesterase (BChE) activities in sheep blood. In vitro, IC50 values were similar after CPF or CPF plus CPM incubations. The pour‐on coadministration of recommended doses of CPF and CPM did not cause a significant inhibition of AChE and BChE in sheep blood. Only slight percentages of inhibition of their catalytic activities were observed when both drugs were given at 4‐fold higher dose rates. The lower systemic availability of topical administration of OPs in sheep may help to explain the lower degree of inhibition of blood AChE and BChE in vivo. The results emerged from this research are a further contribution to the knowledge of the risks of implementing higher dosage regimens of OPs‐containing antiparasitic formulations.     

A free ride: Is long-term omeprazole therapy safe and effective?

Omeprazole has been widely used in the horse for nearly 20 years. Yet, to date, few studies have evaluated its safety with specific regards to the adverse effects reported in human medicine. Recent studies on omeprazole in the horse have highlighted the potential for rebound gastric hyperacidity at the time of discontinuation of therapy, for decreased calcium absorption during administration and for disruption to hindgut function when administered alongside non-steroidal anti-inflammatory drugs. Unlike human medicine, no clear evidence exists for a link between omeprazole administrations and an increased risk of fractures in the horse. However, evidence exists that the proposed pathophysiological pathways for increased fracture risk which are present in human medicine are also present in the horse. Limited evidence suggests that decreased efficacy may occur over time with long-term omeprazole administration.     

Advances in Exotic Mammal Clinical Therapeutics

It is imperative that the veterinarian treating exotic companion mammals stay abreast of the latest developments relating to medications and drug delivery approaches for safety and efficacy. Sustained-release formulations of commonly used drugs, as well as newer routes for administration of therapeutic agents, allow the veterinarian treating exotic companion mammals to reduce the stress associated with drug administration. Interactions can occur between vehicle and drugs when formulations are compounded; therefore, research studies are warranted regarding potential problems associated with these formulations. However, newer studies have been published that provide the basis for exploring the use of different vehicles, frequency of dosing, and drug delivery techniques for various classes of drugs in exotic mammals. The goals of this review are to not only evaluate new medications or uses for medications in companion exotic mammal patients but also review new methods of drug delivery that might be useful to the veterinarian who treats these animals.     

Comparative in vitro characterization of moxidectin and doramectin percutaneous absorption through bovine skin

Topical formulations have achieved worldwide acceptance in veterinary medicine because their administration is an easy, less labor-intensive and nonstressing form. Any chemical compound that comes in contact with the skin has the potential to be locally and/or systemically absorbed. However, many factors related to the features of animal skin, composition of the topical formulation and to the drug itself can determine marked differences in the percutaneous absorption process. The aim of the current work was to characterize the pattern of in vitro percutaneous absorption for moxidectin (MXD) and doramectin (DRM), two of the most worldwide used topical macrocyclic lactone antiparasitic compounds in cattle. The work included the development of a simple and inexpensive in vitro assay useful to predict in vivo drug percutaneous absorption in cattle. Both drugs were administered as the commercial formulations intended for their topical administration to cattle. The in vitro studies were carried out using modified Franz-type vertical diffusion cells. Cattle skin slices of 500 μm thickness were prepared using a dermatome to separate the stratum corneum and upper epidermis from dermis and subcutaneous tissue. The receptor medium was sampled up to 72 h postadministration and drug concentrations were measured by HPLC. The parameters used to estimate the comparative in vitro skin permeation showed marked differences between DRM and MXD. A 5.29-fold longer lag time (T(lag)) was observed for DRM. Similarly, the flux (J) (2.93-fold) and the permeation coefficients (K(p) ) (2.95-fold) in cattle skin were significantly higher (P < 0.05) for DRM compared to those obtained for MXD. Additionally, the data obtained from the in vitro permeation studies was correlated with the plasma concentrations of both compounds achieved in vivo in cattle treated with the same topical formulations. Correlation coefficients between percentage of drug permeated in vitro vs. percentage of drug absorbed in vivo (up to 48 h post-treatment) were 0.856-0.887 (MXD) and 0.976-0.990 (DRM). However, the highest in vitro-in vivo correlations for both molecules were observed up to 24 h post-treatment A rapid screening method for testing different topical formulations can be achieved with the simple in vitro cattle skin permeation technique described here, which has been successfully adapted to test the comparative percutaneous absorption of MXD and DRM.     

Lack of inhibitory effects of several fluoroquinolones on cytochrome P-450 3A activities at clinical dosage in dogs

Inhibitory effects of several fluoroquinolones (FQs) on liver CYP3A activities were examined by in vitro and in vivo tests in dogs. Midazolam (MDZ) hydroxylation rate was used to determine the CYP3A activities in liver microsomes. Enrofloxacin (EFX), ofloxacin (OFX) orbifloxacin (OBFX) and ciprofloxacin (CFX) were tested. None of the FQs changed Vmax, Km or intrinsic clearance (Vmax/Km) of MDZ. For in vivo test, we examined the effects of oral administration of EFX and OFX on the pharmacokinetics of quinidine (QN), a CYP3A substrate. EFX or OFX (10 mg/kg) was administered once a day for 3 days. QN (2 mg/kg) was intravenously injected at 2 h after the final dose of FQs administration. The same dose of QN was intravenously injected 3 weeks before the start of FQs administration for control. Neither EFX nor OFX changed the pharmacokinetic parameters of QN. These in vitro and in vivo consisted results suggest that these FQs lack the inhibitory effects on CYP3A activities in dogs. Hence, given these results, the risk of drug-drug interaction is unlikely to occur between FQs and CYP3A substrates in clinical situation in dogs.     

Macrophage lysozyme stimulation by fructose-1-6-diphosphate

FDP produces an increase of serum lysozyme concentration which may be related to stimulation of the phagocytic activity. Mice macrophages in vitro produce extracellular and intracellular LSZ (lysozyme) and FDP (fructose-1-6-diphosphate) increases this production. Also in vivo FDP stimulates the macrophages intracellular lysozyme production. The toxic activity in vitro and the protection in vivo against Staphylococcus pyogenes after FDP administration can also be related to macrophage stimulation.     

Mucosal permeability of water-soluble drugs in the equine jejunum: a preliminary investigation

Ussing chambers have been used to study the mucosal permeability of drugs in humans, rats and other species. This data can then be used to develop in vitro/in vivo correlations (IVIVC) for drugs based on the Biopharmaceutics Classification System (BCS). Due to the poor oral bioavailability of many drugs in the horse, this method may be useful for screening drugs before development to determine if they warrant further study. Cephalexin (CPX), marbofloxacin (MAR), metronidazole (MTZ) and fluconazole (FCZ) were chosen for this study based on the wide range of physicochemical properties and bioavailability in the horse. Permeability was ranked as follows: MTZ > FCZ > MAR > CPX. This correlated with the bioavailability (R(2) = 0.633447), the Log P (R(2) = 0.648517), as well as the molecular weight (R(2) = 0.851208) of the drugs. Metronidazole induced a decrease in the tissue transepithelial resistance, suggestive of the possibility of tissue toxicity, which may have falsely increased its permeability. The low permeability of cephalexin across the tissue may indicate a lack of active transporters that are found in other species. From this study, we can conclude that the Ussing chamber is a promising method for determining mucosal permeability in the horse.     

Clinical gene therapy: genes by prescription?

Gene therapy is a medical intervention based on modification of the genetic material of living cells. This technique offers widespread possibilities in treating or preventing diseases. This applies to genetically determined diseases but also to diseases that occur later in life. Cells may be modified ex vivo for subsequent administration to patients, or may be altered in vivo by gene therapy given directly to the subject. To introduce the genetic material in cells, vectors are being used. Currently, most vectors are from viral origin. This requires special precautions when producing viral vectors. Gene therapy is apparently safe, when the proper indications and contra-indications are taken into account. Expectations regarding gene therapy are very high. However, more technological barriers are encountered than foreseen and therefore, the clinical success up to now is limited.     

Drug-induced thrombocytopenia

A variety of drugs may cause thrombocytopenia. Although it occurs more often than drug-induced anemia it is less well understood because techniques for studying drug-platelet-immune interactions have been unavailable until recently. The mechanisms by which drugs cause thrombocytopenia are varied. Bone marrow suppression or increased peripheral destruction of platelets could be involved. Nonimmunologic as well as immunologic mechanisms may also occur. These different mechanisms of drug-induced thrombocytopenia are reveiwed. Diagnostic methods and treatment are also summarized.     

Balanced anesthetic techniques in dogs and cats

The term "balanced anesthesia" refers to the use of a mixture of drugs, such that the advantages of small amounts of drugs are used without having to contend with the disadvantages of large doses of any one drug. In veterinary practice, inhalant drugs are usually administered alone to maintain anesthesia, and balanced anesthetic techniques are rare. Unfortunately, cardiopulmonary function is reduced in dose-dependent fashion by inhalant drugs and deepening the level of anesthesia in order to modify autonomic responses to noxious stimuli may increase morbidity and mortality. This article justifies the use of balanced anesthetic techniques in veterinary practice and describes the advantages gained by the use of nitrous oxide, continuous opioid infusion, epidural/spinal opioid administration, and transdermal opioid administration. These techniques, described in detail in the article, are easy to learn, relatively inexpensive, may decrease patient morbidity and mortality, and will provide the veterinarian with smoother operating conditions.     

Can Flush and Lock Solutions Used in Human Medicine Be Applied to Large Animal IV Therapy: A Systematic Review

A recent shortage of prepackaged heparinized saline (HS) syringes has led to the question of whether or not normal saline (NS) can be used to both flush and lock IV catheters in large animal medicine (LAM). Moreover, several known medication incompatibilities exist with IV heparin administration. This is of particular concern in veterinary medicine where limited to no compatibility data exists between “veterinary only” (non-Food and Drug Administration approved) medications and heparin. Most of the literature on this subject is in human medicine where flushing of peripheral IV lines (PIVL) is done safely and effectively with NS. The jugular lines inserted in LAM have characteristics that are more similar to PIVLs versus most central venous access devices used in human patients. In addition, LAM catheters are of larger diameter than those typically used in human medicine thereby reducing the risk of occlusion. Based on the data evaluated, flushing and locking all LAM catheters with of NS is a reasonable alternative method for maintaining IV patency and eliminating problems associated with medication-related incompatibilities or shortages of prepackaged HS syringes.     

Oral pharmacokinetics of the acidic drugs,diclofenac and sulfamonomethoxine in male Shiba goats

In the present study, we examined the oral pharmacokinetics of the acidic drugs, diclofenac (DF) and sulfamonomethoxine (SMM), which have different physicochemical properties, in Shiba goats. DF and SMM were intravenously and orally administered to 5 male goats using a crossover design. The T_max of DF and SMM were reached 1.5 and 5.6 hr after they have been orally administered, respectively, and this was followed by their slow elimination. The elimination of both drugs was markedly faster after being intravenously rather than orally administered, which indicated flip-flop phenomena after the oral administration. The mean absorption times (MATs) of DF and SMM were 6 and 15 hr, respectively. This slow absorption may have been due to slow gastric emptying in goats. The large difference observed in MATs between DF and SMM may have been because DF, which is more lipophilic than SMM, was partly absorbed from the forestomach. Therefore, these results suggest that the absorption of highly lipophilic drugs from the forestomach may be markedly high in Shiba goats. In case of drugs whose elimination is quite fast, their efficacies may appear from the early stage after oral administration even in ruminants, because elimination rate is the determinant factor of T_max in flip-flop phenomena. Such drugs may be used orally even in ruminants.     

Effects of the NSAIDs Meloxicam and Indomethacin on Cartilage Proteoglycan Synthesis and Joint Responses to Calcium Pyrophosphate Crystals in Dogs

NSAIDs are a major cause for concern for their propensity to cause joint deterioration in canine, as in human, patients receiving these drugs for treatment of pain in osteoarthritis and other acute and chronic painful conditions. To determine the potential effects of the new NSAID meloxicam on cartilage integrity, the effects of this drug on proteoglycan biosynthesis in vitro and ex vivo were compared with those of indomethacin, a known inhibitor of sulphated proteoglycans that accelerates joint injury in human osteoarthritis.In vitro cartilage proteoglycan synthesis from a radiosulphate precursor was unaffected by 0.5–10.0 mol/L meloxicam but was significantly inhibited by 50 mol/L indomethacin after 6 or 24 h incubation of femoral or tibial cartilage explants in organ culture. This is in accord with previous observations in human or porcine articular cartilage under the same culture conditions.Studies were performed in vivo to establish the effects of the NSAIDs on joint integrity. This involved determining cartilage proteoglycan synthesis ex vivo, leukocyte, fluid and protein accumulation, as well as pain relief. Thus, meloxicam (0.2 mg/kg i.v.×3 doses) or indomethacin (0.5 mg/kg i.v.×3 doses) was given for 26 h and the effects were compared with a control (1.0 ml saline i.v.×3 doses) in dogs in which acute inflammation had been induced by intra-articular (i.a.) injection of calcium pyrophosphate dihydrate (CPPD) crystals into the right stifle joint, an equivalent volume of saline being injected into the left stifle joint as a control. No effects were observed of the treatment with the NSAIDs on ex vivo sulphated proteoglycan synthesis. The lack of the expected inhibitory effects of indomethacin may be related to the relatively low plasma concentrations of this drug obtained during the 26 h period of treatment.The pain response, which was elicited up to 6 h following i.a. injection of CPPD crystals, was totally prevented by the treatment with meloxicam and to a lesser extent with indomethacin. There were no effects from the drug treatment on synovial inflammatory reactions (fluid and cell accumulation), although the protein concentration of the exudate was reduced by meloxicam. This indicates that, at the doses given, it was possible to discriminate the analgesic action from the anti-inflammatory action of the two NSAIDs, this being achieved at relatively low plasma concentrations of these drugs.In conclusion, while relatively high therapeutic concentrations of indomethacin inhibit cartilage proteoglycan synthesis, this is not an effect seen even at high concentrations of meloxicam. Furthermore, the lack of effects on proteoglycan synthesis was evident when these two drugs were given in vivo to dogs. However, the signs of pain, but not the inflammation in the joint, were relieved by low plasma concentrations of the drugs. Meloxicam may thus be safely employed for acute analgesia without the potential risks of joint cartilage damage that occurs with indomethacin given at anti-inflammatory doses for long periods of time.     

The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics

Pharmacokinetic-pharmacodynamic (PK/PD) surrogate indices (AUIC, AUC/MIC, C(max)/MIC, T>MIC) for measuring antibiotic efficacy are presented and reviewed. As clinical trials are not sufficiently sensitive to establish a dosage regimen which guarantees total bacteriological cure (Pollyanna phenomenon), PK/PD indexes have been proposed from in vitro, ex vivo, and in vivo infection models and subsequently validated in retrospective or prospective human clinical trials. The target value for time-dependent antibiotics (beta-lactams, macrolides) is a time above the MIC (T>MIC) of 50-80% of the dosage interval, while for concentration-dependent antibiotics (quinolones and aminoglycosides), the area under the inhibitory curve (AUIC, or more simply AUC/MIC of about 125h) is the best surrogate indicator of activity. Using the latter drugs, high concentrations achieved early during therapy are desirable to prevent the development of resistance. A C(max)/MIC ratio greater than 10-12 seems to be an appropriate target for aminoglycosides.